Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower Kd...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bi-allelic variants in the ribosomal protein RPS6KC1 cause a complex neurodevelopmental disorder.

American journal of human genetics·2026
Same author

Mitochondria and Lipid Defects in Hereditary Progranulin-Related Frontotemporal Dementia.

Cells·2026
Same author

Multivalent Interactions between Chaperone and Ribosome-Nascent Chain Complex Revealed by High-Speed AFM and MD Simulations.

ACS nano·2025
Same author

Nickel Doping Unlocks Ambient-Condition Photostability in Individual Cesium Lead Bromide Perovskite Quantum Dots.

Nano letters·2025
Same author

Bi-allelic variants in the ribosomal protein RPS6KC1 cause a complex neurodevelopmental disorder.

American journal of human genetics·2025
Same author

Machine Learning Approach for Predicting Drug-Like Molecules Targeting Calmodulin Pathway Proteins.

Journal of chemical information and modeling·2025
Same journal

PACEff Builder: An Efficient Platform for Constructing PACE Hybrid-Resolution Models for Molecular Dynamics Simulations of Aqueous Protein, Peptide Assembly, and Membrane Protein Systems.

Journal of chemical information and modeling·2026
Same journal

TransKla: A Local-Global Cross-Attention Based Transformer Approach for Prediction of Lysine Lactylation Sites.

Journal of chemical information and modeling·2026
Same journal

CondenSimAdapter: A Versatile Builder for Multiscale Simulations of Protein Condensates with Broad Force-Field Compatibility and Robust Dense-Phase Relaxation.

Journal of chemical information and modeling·2026
Same journal

Simulation Guided Design of a Potentially Hyperactive Ice Nucleating Protein.

Journal of chemical information and modeling·2026
Same journal

Setting the Bases of the Photogenotoxicity of <i>p</i>-Aminobenzoic Acid.

Journal of chemical information and modeling·2026
Same journal

Probing Charge-Controlled Inter-Domain Flexibility: Integrating Experimental and Coarse-Grained Approaches.

Journal of chemical information and modeling·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Computational Analysis of ELOVL6 Structure and Inhibition for Rational Drug Design.

Markel G Ibarluzea1,2, Rafael Ramis1,2, Martin Fuentetaja1,2

  • 1Physics Department and EHU Quantum Center, Universidad del País Vasco-Euskal Herriko Unibertsitatea, UPV/EHU, Bilbao 48080, Spain.

Journal of Chemical Information and Modeling
|June 5, 2026
PubMed
Summary
This summary is machine-generated.

ELOVL6 enzyme

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 6, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • ELOVL6 is crucial for fatty acid elongation, converting C16 to C18 fatty acids.
  • Dysregulation of ELOVL6 is implicated in metabolic and neurodegenerative diseases.
  • Lack of structural data and mechanistic insight hinders ELOVL6 inhibitor development.

Purpose of the Study:

  • Investigate the structural basis of ELOVL6 function and inhibition using computational methods.
  • Identify substrate binding pathways and conformational changes upon ligand interaction.
  • Provide insights for structure-based drug design targeting ELOVL6.

Main Methods:

  • Structure prediction
  • Molecular dynamics (MD) simulations
  • Free energy calculations
  • Inhibitor binding pocket analysis
  • Homology comparisons

Main Results:

  • Identified the most stable substrate binding pathway for ELOVL6.
  • Characterized conformational dynamics related to ligand binding.
  • Confirmed active site targeting by known inhibitors and validated binding affinities.
  • Pinpointed key residues for ELOVL6 selectivity over homologous enzymes.

Conclusions:

  • Established a mechanistic framework for ELOVL6 inhibition.
  • Provided insights for rational drug design of ELOVL6-targeting therapeutics.
  • Laid the groundwork for optimizing ELOVL6-based therapies for associated diseases.